Study M690
Study name | Chai C 2021 |
Title | Anti-depressant effect of Zhi-zi-chi decoction on CUMS mice and elucidation of its signaling pathway |
Overall design | The aim of this study was to evaluate the effect of Zhi-zi-chi decoction on relieving depression via behavioral tests, serum metabolomics and signaling target expression analysis on chronic unpredictable mild stress (CUMS) model mice. Balb/c mice were divided into the following 7 groups (n = 10 in each group): (1) control group, (2) Zhi-zi-chi decoction control group (no stress, plus vehicle treatment), (3) CUMS group, (4) CUMS + fluoxetine group (stressor plus fluoxetine treatment at the dose of 3 mg/kg), (5) CUMS + low dose of Zhi-zi-chi decoction group (stressor plus Zhi-zi-chi decoction treatment at the dose of 5 g/kg), (6) CUMS + middle dose of Zhi-zi-chi decoction group (stressor plus Zhi-zi-chi decoction treatment at the dose of 10 g/kg), and (7) CUMS + high dose of Zhi-zi-chi decoction group (stressor plus Zhi-zi-chi decoction treatment at the dose of 20 g/kg). The CUMS stress procedure lasted for 4 weeks, and drugs were administered via intragastric once per day for 3 weeks after stress. |
Study Type | Type1; Type2; |
Data available | Unavailable |
Organism | Mouse; Balb/c mouse; |
Categories of depression | Animal model; Chronic mild stress model; Chronic mild stress model; |
Criteria for depression | Sucrose preference test, forced swimming test, tail suspension test |
Sample size | 70 |
Tissue | Peripheral; Blood; Serum; |
Platform | MS-based; LC-MS: ultra-fast liquid chromatography system (Shimadzu Corporation UFLC XR, Kyoto, Japan) with triple time-of-flight mass spectrometer (TripleTOF 5600 system, AB Sciex, Foster City, CA, USA); |
PMID | |
DOI | |
Citation | Chai C, Jin B, Yan Y, et al. Anti-depressant effect of Zhi-zi-chi decoction on CUMS mice and elucidation of its signaling pathway. J Ethnopharmacol. 2021;266:113283. |
Metabolite | Pyroglutamic acid; L-Tryptophan; L-Proline; Arachidonic acid; L-Tyrosine; Uridine; LysoPC(16:0); Propionylcarnitine; Oxoglutaric acid; Uric acid; Creatine; 4-Hydroxyproline; LysoPC(18:0); Glycerophosphocholine; L-Carnitine; PC(36:4); PC(38:4); PC(38:6); LysoPC(15:0/0:0); Pipecolic acid; LysoPC(16:1/0:0); PC(36:3); LysoPC(20:4); Sphingosine 1-phosphate; Sphingosine; LysoPC(20:0/0:0); 3-O-Sulfogalactosylceramide (d18:1/20:0); PE(40:6); PC(40:7); PE(38:6); PI(36:4); PI(38:4); PC(34:3); LysoPC(20:3); Sphinganine; LysoPC(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/0:0); LysoPC(17:0/0:0); Leukotriene A4; LacCer(d18:1/12:0); Cholesterol sulfate; PC(15:0/22:5(4Z,7Z,10Z,13Z,16Z)); LysoPC(24:1(15Z)/0:0); LysoPC(P-18:1(9Z)); PE(40:7); 3-O-Sulfogalactosylceramide (d18:1/18:1(9Z)); PC(38:7); PC(40:8); PC(34:2); PC(40:10); PC(15:0/P-16:0); PC(33:2); PC(18:4(6Z,9Z,12Z,15Z)/P-16:0); 3-Dehydrosphinganine; C5H11NO2; C42H81NO8; LysoPC(18:3); C4H8O3; Deoxyribose; trans-2-Enoyl-OPC8-CoA; SM(d18:0/16:1(9Z)); PC(36:6); C18H32O3; C20H32O3; LysoPC(P-18:0/0:0); LysoPA(18:1(9Z)/0:0); SM(d18:0/14:1(9Z)(OH)); LysoPA(16:0/0:0); |
